NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
复制标题
DOI：
10.1016/j.bbmt.2010.02.005
复制
发表时间：
2010-05
影响因子：
4.3
通讯作者：
Falkenburg, J. H. Frederik
中科院分区：
文献类型：
--
作者：
Miller, Jeffrey S.;Warren, Edus H.;van den Brink, Marcel R. M.;Ritz, Jerome;Shlomchik, Warren D.;Murphy, William J.;Barrett, A. John;Kolb, Hans Jochem;Giralt, Sergio;Bishop, Michael R.;Blazar, Bruce R.;Falkenburg, J. H. Frederik
异基因造血干细胞移植（HSCT）的成功取决于良性干细胞以及能够参与移植物抗肿瘤/白血病（GVL）反应的淋巴细胞的输注。概念的临床证据来源于显示输注淋巴细胞耗尽的造血移植物后复发增加的研究，以及不使用化疗的供体淋巴细胞输注治疗某些疾病复发的疗效。尽管有这些知识，同种异体HSCT后复发是常见的，在高危疾病患者中复发率接近40%。在这篇综述中，我们涵盖了基础生物学和潜在的应用，利用适应性T细胞反应，次要的组织相容性抗原，收缩和抑制机制，阻碍免疫反应，适应性B细胞反应和先天性NK细胞反应，所有精心策划的GVL反应。需要精确平衡免疫应答以有利于GVL而没有有害的移植物抗宿主病（GVHD）的最佳策略，以防止复发，治疗持续性疾病并提高HSCT后的无病生存率。
The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of benign stem cells as well as lymphocytes capable of participating in a graft-versus-tumor/leukemia (GVL) reaction. Clinical proof of concept is derived from studies showing increased relapse after the infusion of lymphocyte depleted hematopoietic grafts as well as the therapeutic efficacy of donor lymphocyte infusions without chemotherapy to treat relapse in some diseases. Despite this knowledge, relapse after allogeneic HSCT is common with rates approaching 40% in those with high-risk disease. In this review, we cover the basic biology and potential application to exploit adaptive T cell responses, minor histocompatibility antigens, contraction and suppression mechanisms that hinder immune responses, adaptive B cell responses and innate NK cell responses, all orchestrated in a GVL reaction. Optimal strategies to precisely balance immune responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against relapse, treat persistent disease and improve disease-free survival after HSCT.
登录
查看更多内容
DOI：
10.1073/pnas.96.15.8639
发表时间：
1999-07-20
影响因子：
11.1
作者：
Bonnett, D;Warren, EH;Riddell, SR
通讯作者：
Riddell, SR
影响因子：
15.9
作者：
Berger, Carolina;Jensen, Michael C.;Riddell, Stanley R.
通讯作者：
Riddell, Stanley R.
DOI：
10.1084/jem.183.6.2645
发表时间：
1996-06-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Baker MB;Altman NH;Podack ER;Levy RB
通讯作者：
Levy RB
影响因子：
20.3
作者：
Bollard, CM;Rössig, C;Rooney, CM
通讯作者：
Rooney, CM
影响因子：
4.4
作者：
Blazar, BR;Carreno, BM;Taylor, PA
通讯作者：
Taylor, PA